Collectively, silencing AURKA reinforced the therapeutic effects of CHOP on reducing viability and promoting apoptosis of DLBCL cell via suppressing β-Catenin and RAS-ERK1/2 pathway. The gene discussed is AURKA; the disease is diffuse large B-cell lymphoma.